Population screening for cancer
230 results
1 - 100
Population screening for cancer - Essentials
- Benefits and harms
- Screening programmes recommended to be included in a public health policy
- Screening programmes that have a known effect on mortality but not yet recommended to be included in a public health policy
- Screening programmes not recommended to be included in a public health policy
- References
Screening tests for endometrial cancer in the general population- Cytology versus HPV testing for cervical cancer screening in the general population
- Screening for colorectal cancer using the faecal occult blood test, Hemoccult
USPSTF 2017 recommends against screening for thyroid cancer in asymptomatic adults (D recommendation)- Human papillomavirus (HPV) infection
- HPV-based screening can replace cytology-based screening for cervical cancer
- Colorectal cancer screening modalities: variable uptake, variable yield (SAVE)
- Consequences of screening for lung cancer (NELSON)
- Screening mammography overdiagnoses women with breast cancer
- HPV DNA screening detects CIN3 and cancer earlier
- Colon cancer screening may be beneficial for Lynch syndrome
- Elders want a say in when to stop cancer screenings
- Ovarian cancer screening does not improve outcomes (UKCTOCS)
- Lung cancer screening is cost effective, but only if done correctly
- Screening and prevention of colorectal cancer
- Screening for ovarian cancer with CA-125/ultrasound algorithm does not reduce mortality (UKCTOCS)
- The full truth about prostate cancer screening is suppressed again (ERSPC)
- High false positive rate in repeated, multimodal screening for cancers (PLCO)
- Supplemental MRI screening in women with very dense breasts reduces interval cancer rate but may cause overdiagnosis (DENSE)
- Systematic review: lung cancer screening with CT decreases mortality but with significant harms
- Navigation program slightly decreases time to resolution of abnormal cancer screening results
- New screening test for nasopharyngeal cancer accurate but not proven to improve patient outcomes
- Mailing FIT or gFOBT directly to patients increases uptake of colorectal cancer screening
- Have the USPSTF recommendations against screening caused more aggressive prostate cancer?
- Screening CA-125 and transvaginal ultrasound does not reduce ovarian cancer mortality
- Annual screening chest x-ray does not reduce lung cancer mortality
- Prostate cancer screening: no mortality benefit after 15 years of follow-up (PLCO)
- FIT more acceptable with better detection rate than gFOBT for colorectal cancer screening
- USPSTF 2018 recommends against screening for ovarian cancer in asymptomatic women (D recommendation)
- USPSTF 2019 recommends against screening for pancreatic cancer in asymptomatic adults (D recommendation)
- Prostate cancer screening: no mortality benefit after 13 years of follow-up (PLCO)
- Lung cancer screening with low-dose CT does not affect smoking cessation rates
- Interventions to encourage uptake of cancer screening for people with severe mental illness
- Volume-based low-dose CT screening reduces lung cancer–specific mortality (NELSON)
- Limited benefit for routine cervical cancer screening with co-testing versus HPV testing alone
- Even before the new guidelines, a majority of women stated a preference for breast cancer screening in their 40s
- HPV-based screening more effective to prevent invasive cervical cancer than cytology alone
- Fecal DNA testing = Hemoccult Sensa for colon cancer screening
- Colon cancer screening with fecal immunochemical tests: False-positive rates vary
- USPSTF 2018 recommends counseling 55 to 69-year-old men on benefits and harms of prostate cancer screening (C recommendation)
- After community lung cancer screening, rates of follow-up imaging are lower but the rates of some procedures are higher
- USPSTF 2021 recommends annual lung cancer screening based on shared decision-making in high-risk adults (B recommendation)
- Screening for nasopharyngeal cancer
- Results of fecal immunochemical tests for colorectal cancer screening not affected by NSAIDs, aspirin, or anticoagulants
- Screening for colorectal cancer using the faecal occult blood test, Hemoccult
- PSA test in prostate cancer screening
- Screening programmes for the early detection and prevention of oral cancer
- Screening for lung cancer
- Scottish screening: 0 cases of invasive cervical cancer in women who received at least 1 dose of bivalent HPV vaccine at 12 or 13 years of age
- Women with normal Pap smears in their 50s unlikely to develop cervical cancer as they age
- Screening programmes for the early detection and prevention of oral cancer
- Digital mammography: more cancers detected, more recalls, more overdiagnosis than film-based mammography
- Cell-free DNA blood test 83% sensitive for colorectal cancer, 13% sensitive for advanced adenoma; mortality data lacking (ECLIPSE)
- USPSTF 2016: updated recommendations for colorectal cancer screening
- Pedigree identifies hereditary breast cancer syndromes
- Lung cancer screening requires additional imaging in 40% of patients in real world
- Health monitoring in the elderly
- Strategies for increasing the participation of women in community breast cancer screening
- Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality
- Better estimate of prostate cancer risk based on the number of close relatives with prostate cancer and their age at diagnosis
- Two thirds of reduction in breast cancer mortality due to therapy advances
- Signs and symptoms can indicate an increase in the likelihood of ovarian cancer
- Observational study finds lower colorectal CA-specific mortality with colonoscopy
- Guaiac‐based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average‐risk individuals
- Aspirin = screening to prevent colorectal cancer mortality
- Self examination for breast cancer
- Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
- Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk